Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2017

2017-07-26
Price :
Published : Jul-2017
No. of Pages : 68
order by fax Inquire before Buying request discount
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials 33
Prominent Drugs 35
Clinical Trial Profile Snapshots 37
Appendix 66
Abbreviations 66
Definitions 66
Research Methodology 67
Secondary Research 67
About GlobalData 68
Contact Us 68
Source 68

List of Tables
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 11
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 21
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 30
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36

List of Figures
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 11
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 30
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35
GlobalData Methodology 67
Filed in: Pharmaceutical
Publisher : GlobalData